Ionis Pharmaceuticals IONS Deferred Tax Assets Sale Of Future Royalties
Deferred Tax Assets Sale Of Future Royalties at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept ions:DeferredTaxAssetsSaleOfFutureRoyalties.
The official record: Ionis Pharmaceuticals’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's deferred tax assets sale of future royalties.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's deferred tax assets sale of future royalties?
- Ionis Pharmaceuticals (IONS) reported deferred tax assets sale of future royalties of $156.87M in Q4 2025.
- What does deferred tax assets sale of future royalties mean?
- Future tax benefits related to the timing of income recognition from royalty sales.
- How do you interpret deferred tax assets sale of future royalties?
- An increase suggests the company has entered into royalty monetization agreements that create temporary tax timing differences.
- How does deferred tax assets sale of future royalties compare across companies?
- Specific to companies with intellectual property monetization strategies.